Development
Johnson & Johnson's lumateperone ranks highest in adjunctive major depressive disorder network meta-analysis
Johnson & Johnson (NYSE: JNJ) reported that lumateperone (Caplyta) ranked highest across four efficacy measures in a network meta-analysis comparing...
Oncolytics' pelareorep shows durable responses in second-line KRAS-mutant colorectal cancer
Oncolytics Biotech (Nasdaq: ONCY) reported a median duration of response of 19.5 months for pelareorep in combination with bevacizumab and FOLFIRI in...
Atsena's Atsn-201 achieves foveal schisis closure in X-linked retinoschisis Phase I/II/III trial
Atsena Therapeutics reported interim six-month data from Part B of the Phase I/II/III LIGHTHOUSE trial evaluating ATSN-201 in X-linked retinoschisis,...
Takeda's Tak-881 meets primary endpoint in Phase II/III primary immunodeficiency disease trial
Takeda (TSE:4502/NYSE:TAK) reported that TAK-881, an investigational immune globulin subcutaneous 20% formulation facilitated by recombinant human...
Celcuity's gedatolisib triplet beats alpelisib in Phase III breast cancer trial
Celcuity (Nasdaq: CELC) reported that gedatolisib combined with fulvestrant and palbociclib met the primary endpoint of the Phase III VIKTORIA-1 trial,...
Corcept’s dazucorilant shows large survival signal in ALS despite Phase II primary endpoint miss
Corcept Therapeutics (Nasdaq: CORT) reported two-year overall survival data from its Phase 2 DAZALS study of dazucorilant in amyotrophic lateral sclerosis,...
Johnson & Johnson discontinues JNJ-90014496 CAR-T programs in large B-cell lymphoma
Johnson & Johnson has announced the discontinuation of two investigational CAR-T cell programs in large B-cell lymphoma, citing portfolio priorities and its...
Can-Fite's namodenoson shows durable disease control in Phase IIa advanced pancreatic cancer trial
Can-Fite BioPharma (NYSE American: CANF) reported Phase 2a data for namodenoson in advanced pancreatic adenocarcinoma showing stable disease in more than...
Cadrenal's CAD-1005 advances to Phase III trial for heparin-induced thrombocytopenia treatment
Cadrenal Therapeutics (Nasdaq: CVKD) announced that it has completed an End-of-Phase 2 meeting with the FDA for CAD-1005, its investigational...
Novo Nordisk's denecimig reduces hemophilia A bleeding rates by up to 99% in Phase III trial
Novo Nordisk's (Novo) investigational denecimig hemophilia A therapy reported Phase III data showing the bispecific antibody cut annualized bleeding rates...
AstraZeneca, Amgen participate in FDA pilot of real-time clinical trials
The US FDA announced on April 28 that it has successfully initiated two proof-of-concept studies designed to transmit trial endpoints and data signals to...
Boehringer Ingelheim's survodutide achieves 16.6% weight loss in Phase III obesity trial
Boehringer Ingelheim reported that survodutide, its investigational glucagon/GLP-1 dual agonist, produced an average body weight reduction of 16.6% over 76...
Zealand Pharma and Roche advance petrelintide into Phase III for chronic weight management
Zealand Pharma (Nasdaq: ZEAL) and Roche announced they will advance petrelintide into Phase 3 development for chronic weight management following Phase 2...
Newron Pharma's evenamide faces FDA enrollment hold after patient death
Newron Pharmaceuticals said the US Food and Drug Administration has placed a clinical hold on new patient enrollment at US sites in its Phase III ENIGMA-TRS...
Pfizer's elranatamab meets Phase III primary endpoint in relapsed or refractory multiple myeloma
Pfizer (NYSE: PFE) reported that elranatamab (Elrexfio) met its primary endpoint in the Phase III MagnetisMM-5 trial, demonstrating a statistically...
The AllSci Brief
Systematic R&D and deal news. Daily.